Clinics in Laboratory Medicine 1999: Vol 19 Index

25 Pages·1999·4.8 MB·English

CUMULATIVE INDEX 1999
Volume 19
DIAGNOSTIC PEDIATRIC HEMATOLOGY, pages 1-264
March
RETHINKING THE CLINICAL LABORATORY, pages 265-467
June
FOOD-BORNE DISEASES, pages 469-712
September
OUTCOMES IN PATHOLOGY, pages 713-908
December
Note: Page numbers of article titles are in boldface type
ABO blood group incompatibility, erythroblastic, 191, 216-218
hemolytic anemia in, 89-91 erythroleukemia (M6), 191, 216-218
Abscess, liver, in amebiasis, 607, 615 flow cytometry in, 196-197
Accessory cholera toxin, 538 genetic factors in, 188-189, 197-201
Acidemia, fetal, erythroblast count in, hybrid, 221-223
19-20 immunophenotyping of, 190, 193-197
Acquired immunodeficiency syndrome. megakaryoblastic (M7), 191, 218-219
See Human immunodeficiency virus mixed lineage, 221-223
infection. monoblastic (M5), 191, 213-216
Activated partial thromboplastin time, in morphologic features of, 190-192
pediatric patients, 51-52 myeloblastic, with minimal
in heparin therapy monitoring, 60-61 differentiation (MO), 219-221
Acute lymphoblastic leukemia, in pediatric without differentiation (M1), 191,
patients, 169-186 201-292
cytochemical characteristics of, 191 myelocytic, with differentiation (M2),
flow cytometry in, application of, 172 191, 202-206
prognostic value of, 178-183 myelomonocytic (M4), 191, 210-213
technical considerations in, 170-172, oligoclonal, 221-223
176-178 promyelocytic (M3), 191, 206-210
genotypic features of, 180-183 undifferentiated or unclassifiable,
immunophenotypic classification of, 224-225
172-175 with atypical lymphoid-associated
morphologic evaluation in, 169-172, antigen expression, 221-224
19] Adenitis, mesenteric, in Yersinia
undifferentiated or unclassifiable, pseudotuberculosis infections, 531-532
224-225 Adhesins, Escherichia coli, 507
Acute myeloid leukemia, in pediatric Aeromonas caviae infections, 567
patients, 187-237 Aeromonas hydrophila infections, 565, 567,
basophilic variant of, 206 569
biclonal, 221-223 Aeromonas infections, 564-571
biphenotypic, 221--223 clinical features of, 570
chimeric, 221-223 complications of, 571
classification of, 192 diagnosis of, 570-571
clinical features of, 189-190 epidemiology of, 568-569
cytogenetics of, 197-201 organisms causing, characteristics of,
environmental factors in, 188 564-565
epidemiology of, 187-188 identification of, 566-567
886 CUMULATIVE INDEX 1999
Aeromonas infections (Continued) E-Aminocaproic acid, in platelet disorders,
isolation of, 565-566 84
mesophilic, 565 AML. See Acute myeloid leukemia.
psychrophilic, 565 AML1I gene, in leukemia, 199-201, 204
typing of, 567 Amniocentesis, in prenatal diagnosis,
virulence factors of, 567-568 239-240
pathogenesis of, 568 Ampicillin, in Listeria monocytogenes
prevention of, 571 infections, 564
treatment of, 571 Anemia(s), aplastic. See Aplastic anemia(s).
Aeromonas salmonicida infections, 565 Cooley’s, 101-102
Aeromonas veronii infections, 567 Diamond-Blackfan. See Diamond-Blackfan
Aggregative adherence fimbriae, of anemia.
Escherichia coli, 510 Fanconi’s, 114-123, 245
Aggregometer, platelet, 77 hemolytic. See Hemolytic anemia.
Agranulocytosis, in Kostmann’s syndrome, in Pearson’s syndrome, 126
129 in reticular dysgenesis, 127
in reticular dysgenesis, 127 macrocytic, in cartilage-hair hypoplasia,
AIDS. See Human immunodeficiency virus 125
infection. in Diamond-Blackfan anemia, 128-129
DL-Alanine-B-naphthylamide test, for physiologic, of infancy, 87
Listeria monocytogenes, 557 reticulocyte count in, 17
Albendazole, in trichinosis, 653 sickle cell, 106-109
ALL. See Acute lymphoblastic leukemia. Anisakiasis, 640, 654-655
Alloimmune hemolytic anemia, in Anisocytosis, in spherocytosis, 93
neonates, 89-92 Antenatal diagnosis. See Prenatal diagnosis.
in ABO incompatibility, 91 Antibiotics, appropriate use of, decision-
in maternal autoimmune disease, 92 making for, laboratory support of,
in minor blood group incompatibility,
868-873
91-92 resistance to, in Campylobacter, 496-497
Rh antigen-related, 89-91 Antibody(ies), antiphospholipid,
Alloimmune thrombocytopenia, in
thromboembolism and, 59-60
pediatric patients, treatment of, 84
antiplatelet, measurement of, 78-79
prenatal diagnosis of, 245-246
monoclonal, in benign versus malignant
Allowed relationships, in information
neoplasia differentiation, 806-808
model, 391 in infection diagnosis, 800
Alpha-fetoprotein, screening for, in
maternal blood, 242 in leukemia diagnosis, 171, 190, 193-
Alternative careers. See Careers, alternative. 197
Anticardiolipin antibodies,
Amebapore, 604
thromboembolism and, in pediatric
Amebiasis, 601-619
asymptomatic, treatment of, 615 patients, 59-60
clinical features of, 606-607 Anticoagulants, oral, monitoring of, in
diagnosis of, 608-615 pediatric patients, 61-62
epidemiology of, 605-606 Antigen(s), erythrocyte, in pediatric
organisms causing, characteristics of, patients, 12
602-604 lymphocyte, in pediatric patients, 30
types of, 601-602 lymphoid-associated, atypical expression
versus nonpathogenic amebae, 608 of, in acute myeloid leukemia, 221-
pathogenesis of, 604-605 224
prevention of, 616 myeloid, in leukemia, 179
treatment of, 615-616 Antiphospholipid antibodies,
Ameboma, 607 thromboembolism and, in pediatric
Amegakaryocytic thrombocytopenia, patients, 59-60
diagnosis of, 120, 127 a,-Antiplasmin, in pediatric patients, 47-49
genetic factors in, 120, 127 Antiplatelet antibodies, measurement of,
hematology of, 116, 127 78-79
hematopoietic culture in, 117, 127 Antithrombin, deficiency of, prenatal
malignancies in, 119, 127 diagnosis of, 247
physical anomalies in, 115, 127 thromboembolism in, 57
American Society of Clinical Pathologists, normal values for, in pediatric patients,
Web site of, 444-445 42, 45
CUMULATIVE INDEX 1999 887
Antithrombotic therapy, monitoring of, in Balantidium coli infections, 632-636
pediatric patients, 60-63 clinical features of, 634
Antitoxin, botulinum, 588 diagnosis of, 634-635
APC gene, molecular tests for, 819 epidemiology of, 636
API Listeria strip, 557 organism causing, 633
Aplastic anemia(s), familial, diagnosis of, prevention of, 636
120, 128 treatment of, 635
genetic factors in, 120, 128 Bar codes, in specimen container
hematology of, 116, 128 identification, 308-309
hematopoietic culture in, 117 in specimen tracking, 312-313
malignancies in, 119 Basophilia, in transient leukemia, 158
physical anomalies in, 115 BCL-2 proteins, as brain tumor markers,
in dyskeratosis congenita, 123 841-842
in Fanconi’s anemia, 114 Beef tapeworm infections, 640, 646-648
Benign cephalic histiocytosis, 142
in Shwachman-Diamond syndrome, 124
Bernard-Soulier syndrome, 82
Arizona infections, 469-470
Bioengineering, careers in, 455-456
Arterial thromboembolism, clinical
Biotechnology, careers in, 455-456
features of, in pediatric patients, 56 Bismuth sulfite agar, for Salmonella, 470
Arthritis, reactive, in Yersinia enterocolitica
Bladder cancer, molecular tests for, in early
infections, 528-529
disease detection, 826
Aspirin, platelet disorders from, 83
Blastocystis hominis infections, 601, 607-608
Association of Directors of Anatomic and
diagnosis of, 608-612
Surgical Pathology, Web site of, Bleeding. See Hemorrhagic disorders.
445-446 Bleeding time test, in pediatric patients,
Audit systems, for diagnostic errors, 52-53
744-750 in platelet disorders, 74-76
Auer bodies, in fetus, 5 Blood film examination, in transient
Autoimmune hemolytic anemia, in leukemia, 161
pediatric patients, 88-89 Blood group antigens, immunostaining for,
Automation, careers in, 457 in foreign tissue, 801
in regional laboratory network, 314-315 Blood sampling, fetal, 241-242
Autopsy, clinicopathologic correlations of, pediatric, problems with, 1, 7
731-736 Blood transfusions, molecular testing for,
report adequacy in, 732-733 822
report timeliness in, 733, 735-736 Yersinia enterocolitica transmission in, 527
turnaround time and, 733-735 Blood vessels, hemostatic properties of, in
pediatric patients, 50-51
Bone(s), Langerhans’ cell histiocytosis of,
139-140
B lymphocytes, normal values for, in Bone marrow, examination of, in
pediatric patients, 22-23 hemophagocytosis, 148
ontogeny of, acute lymphoblastic leuke- in transient leukemia, 163
mia and, 173 Langerhans’ cell histiocytosis of, 140
Bacillus cereus food poisoning, 590-593, 595 normal cell populations of, in pediatric
diagnosis of, 592-593 patients, 25-30
diarrheal form of, 590-592, 595 Bone marrow failure syndromes, in
emetic form of, 590-591, 595 pediatric patients, 113-133
Bacillus thuringiensis toxins, 591 amegakaryocytic thrombocytopenia,
Bacteremia, Aeromonas, 568, 570 115-117, 119-120, 127
Listeria monocytogenes, 561 cartilage-hair hypoplasia, 115-117,
Plesiomonas shigelloides, 574 119-120, 125-126
Salmonella, 475-476 Diamond-Blackfan anemia, 115-117,
Shigella, 482 119-120, 128-129
Vibrio, 542, 544, 547-548 dyskeratosis congenita, 115-117,
Yersinia enterocolitica, 528 119-120, 123-124
Bacteria, identification of, familial aplastic anemias, 115-117,
immunohistochemistry in, 799-800 119-120, 128
molecular tests in, 822 Fanconi’s anemia, 114-123
Baculovirus-expressed virus-like particles, Kostmann’s syndrome, 115-117,
in enzyme immunosorbent assays, 684 119-120, 129-130
888 CUMULATIVE INDEX 1999
Bone marrow failure syndromes (Continued) isolation of, 494-495
Pearson’s syndrome, 115-117, 119-120, typing of, 496
126-127 pathogenesis of, 491-492
reticular dysgenesis, 115-117, 119-120, prevention of, 497-498
127 resistance in, 496-497
Shwachman-Diamond syndrome, treatment of, 497
115-117, 119-120, 124-125 Cancer. See also specific location.
single cytopenia, 115-117, 119-120, in bone marrow failure syndromes, 119.
128-130 See also specific syndromes.
thrombocytopenia with absent radii, molecular tests for, for genetic predispo-
115-117, 119-120, 130 sition, 817-820
Botulism, 583-590, 595 in early disease detection, 825-826
antitoxin for, 588 in therapy guidance, 827
diagnosis of, 586-588 screening, 823-825
infant, 584-585, 588 morphotyping of, immunohistochemis-
intestinal colonization, 585 try in, 801-805
prevention of, 588-589 staging of, immunohistochemical, 808-
toxins in, 585-586 809
treatment of, 588 versus benign proliferations, immunohis-
types of, 583-585 tochemical separation of, 806-808
wound, 584-585, 588 Capillary blood sampling, in pediatric
Brain, juvenile xanthogranuloma of, 143 patients, 7-8
Langerhans’ cell histiocytosis of, 141 Carcinoma, metastatic, of unknown origin,
tumors of, prognostic markers for, 833- immunohistochemical identification
847 of, 803-805
BCL-2 proteins, 841-842 Cardinality, in information model, 390
cell proliferation, 835-839 Careers, alternative, 453-461
epidermal growth factor receptor, automation, 457
840-841 biotechnology and bioengineering,
p53 protein, 840-841 455-456
telomerase, 839-840 head hunters for, 459
BRCA genes, molecular tests for, 818-819 information sciences, 454-455
Breast cancer, immunohistochemical interview strategies, 459-460
identification of, 807 negotiation strategies, 459-460
molecular tests for, for genetic predispo- pursuit of, 458-459
sition, 818-819 supervisory, 456
in therapy guidance, 827 technical associate, 278
screening, 823-824 tissue engineering, 457-458
Brilliant green agar, for Salmonella, 470 Cartilage-hair hypoplasia, diagnosis of, 120
Bristol strain, of Norwalk virus, 679 genetic factors in, 120, 125-126
Bulletin boards (newsgroups), on Internet, hematology of, 116, 125-126
442-443 hematopoietic culture in, 117, 125-126
Bundle-forming pili, of Escherichia coli, 509 malignancies in, 119, 126
physical anomalies in, 115
Catheter-related thromboembolism, in
pediatric patients, 56
Calicivirus infections. See Norwalk virus CBFB/MYH11 gene, in leukemia, 211
and Norwalk-like virus infections. CD10 (common acute lymphoblastic
CALLA (common acute lymphoblastic leukemia antigen, CALLA), in acute
leukemia antigen, CD10), in acute lymphoblastic leukemia, 174
lymphoblastic leukemia, 174 Cefsulodin-irgasan-novobiocin agar test,
CAMP test, for Listeria monocytogenes, for Aeromonas, 565-566
556-557 for Yersinia enterocolitica, 524
Campylobacter infections, 489-504 Cell culture, hepatitis A virus, 669
clinical features of, 493-494 Central nervous system, juvenile
diagnosis of, 494-497 xanthogranuloma of, 143-144
epidemiology of, 492-493 Langerhans’ cell histiocytosis of, 141
organisms causing, characteristics of, Cerulide, Bacillus cereus, 591-593, 595
489-491 Cervical cancer, screening for, cost-
identification of, 495-496 effectiveness analysis of, 765-769
CUMULATIVE INDEX 1999 889
molecular tests in, 824-825 Clostridium baratii toxins, 583, 585, 587
quality assurance in, in France, Clostridium botulinum toxins. See Botulism.
877-884 Clostridium butyricum toxins, 583, 585, 587
Cervicovaginal cytology, histologic Clostridium perfringens toxins, 589-590, 595
correlations of, in quality assurance, Coagulation system, of pediatric patients,
725-726 40-47
Cestodes infections, 644-650 disorders of, hemorrhagic, 51-55
Diphyllobothrium latum, 640, 644-646 in acute myeloid leukemia, 189-190
Taenia saginata, 640, 646-648 prenatal diagnosis of, 246-247
Taenia solium, 640, 648-650 thromboembolic, 56-60
Chat rooms, on Internet, 448-449 fibrinolytic system, 47-48
Chinese liver fluke infections, 640, 656-658 inhibitors, 42, 45-46
Chloramphenicol, in salmonellosis, 476 proteins, 40-44
Cholera, 537-552 deficiencies of, 53-54, 246-247
clinical features of, 542-544 reference values for, 43-47
diagnosis of, 544-547 screening tests for, 40-41, 51-53
epidemiology of, 541 thrombin regulation, 45, 47
nonepidemic, epidemiology of, 541-542 Cognitive processing, in information
pathogenesis of, 539 integration, 289-290
organism causing, characteristics of, Coli surface antigen, of Escherichia coli, 507
537-539 College of American Pathologists, Web site
identification of, 545-547 of, 445
isolation of, 545 Colonization factor antigen, of Escherichia
strains of, 538 coli, 507
toxins of, 538 Colorectal cancer, molecular tests for, for
pathogenesis of, 540-541 genetic predisposition, 819-820
nonepidemic, 539 screening, 824
prevention of, 548-549 Communication, in networks, 309-311,
severe, 538 346-347
transmission of, 538 markup protocols for, 293-294
treatment of, 547-548 Community Health System (California),
Chorionic villus sampling, in prenatal laboratory re-engineering at,
diagnosis, 240-241 317-336
Chromosomal abnormalities, in acute before redesign, 318
lymphoblastic leukemia, 180-183 economic issues in, 319, 333
in acute myeloid leukemia, 197-201 hospital reorganization impact on,
prenatal diagnosis of, 247 320-324, 327-329
Ciliates, Balantidium coli as, 632-636 information management in, 330-332
Ciprofloxacin, in Escherichia coli infections, in-house testing criteria for, 325-326
516 initial phase of, 318-327
in salmonellosis, 476 main laboratory remodeling in,
in Shigella infections, 483-484 329-330
Classification hierarchy, in data exchange, management of, 320-324
398, 402-403 organization in, 327-329
Clastogenic stress test, for dyskeratosis results of, 334-336
congenita, 124 service agreements in, 326
for Fanconi’s anemia, 118 STAT laboratory of, 329
Clinical perspectives, on laboratory, University Medical Center addition to,
421-432 332-333
change management, 429-431 Concept permanence, in data exchange,
conceptual framework for, 421-423 398
effectiveness, 423-425 Conditionality, in information model, 391
efficiency, 425-426 Confidentiality. See also Privacy.
process flow, 426-429 maintaining, 294-295, 358
Clinical practice decision-making, realizing, 358-359
laboratory support of, 867-876 threats to, 367-368
antibiotic use case study of, 868-873 Consultation, on diagnostic errors, 750
computerized oxygen therapy case Container, specimen, identification of, in
study of, 873-874 regional laboratory networks, 308-309
Clonorchis sinensis infections, 640, 656-658 Context free names, in data exchange, 398
890 CUMULATIVE INDEX 1999
Continuing education, Internet in. See Cyst(s), amebic, 602-603, 606, 609-612
Internet. identification of, 605
traditional, 433-435 Balantidium coli, 633-634
Cooley's anemia, 101-102 Blastocystis hominis, 608
Coracidium, of tapeworm, 645 Giardia lamblia, 622-625, 631-632
Cordocentesis, in blood sampling, 241-242 Cystathione-B-synthase deficiency,
Core binding complex, in leukemia, hyperhomocysteinemia in, 58
199-200 Cysteine-rich surface protein, of Giardia
Core laboratory, rapid-response, in
lamblia, 626
regional network, 321, 325 Cystic fibrosis, molecular tests for, 820-821
Corticosteroids, in platelet disorders, 84
Cysticercosis, 649
Cost utility analysis, 761 Cysticercus, of beef tapeworm, 647
Cost-based (Part A) pathology services,
of pork tapeworm, 649
783-796 Cytochemistry, in transient leukemia, 161
administrative, compensation for, 785,
Cytohistologic correlations, in quality
788
assurance, 724-727
definition of, 784
Cytokines, excessive, in hemophagocytosis,
description of, 783-784
149
diagnostic-related group-based pay-
Cytology, gynecologic, cost-effectiveness
ments for, 785-786
analysis of, 765-769
future of, 792-794 quality assurance in, in France,
patient care impact of, 789-792
877-884
value assignment to, 788-789
histologic correlation with, in quality as-
versus Part B services, 784
surance, 724-727
Cost-benefit analysis, 761
Cost-consequences analysis, 760 rescreening of, in quality assurance, 727
Cost-effectiveness analysis, 757-781 Cytolysin, Vibrio cholerae, 538
benefit description in, 761-762 Cytomegalovirus infections, prenatal
cost description in, 762 diagnosis of, 247
description of, 759-760 Cytopathnet Web site, 446-447
discounting in, 762 CYTOPATHNET-L mailing list, 441
essentials of, 761-764 Cytopenia. See also Pancytopenia.
examples of, 764-769 single, diagnosis of, 120
need for, 757-759 Diamond-Blackfan anemia, 115-117,
of cytology techniques, 765-769 119-120, 128-129
perspective of, 761 genetic factors in, 120
sensitivity analysis in, 762 hematology of, 116
types of, 760-761 hematopoietic culture in, 117
Cost-effectiveness ratios, 760-763 Kostmann’s syndrome, 115-117, 119-
Cost-minimization analysis, 760 120, 129-130
CREB-binding protein defects, in malignancies in, 119
leukemia, 216 physical anomalies in, 115
Culture, Aeromonas, 565-566 thrombocytopenia with absent radii,
Bacillus cereus, 592-593 115-117, 119-120, 130
Campylobacter, 490, 494-495 Cytotoxin, Shigella, 480
Clostridium botulinum, 587
Clostridium perfringens, 590
Edwardsiella tarda, 576
Escherichia coli, 513-515 Data exchange, 385-419
hepatitis A virus, 669 components of, 386-387
Listeria monocytogenes, 554-556 implementable message syntax, 386-
Norwalk viruses, 678 387, 406-415
Plesiomonas shigelloides, 572 information model, 390-397
rotavirus, 698-699 terminology of, 397-406
Salmonella, 470-471 definition of, 385
Shigella, 478 Document Type Definition in, 408-410,
Staphylococcus aureus, 594, 596 413
Vibrio, 545-546 facilitated deployment in, 385
Yersinia enterocolitica, 524-525 message optimization in, 385
C282Y (hemochromatosis) gene, molecular requirements for, 385
tests for, 821 standards for, 387-390
CUMULATIVE INDEX 1999 891
Extensible Markup Language, 294, Disseminated intravascular coagulation, in
389-390, 407, 409, 411, 413-415 pediatric patients, 54-55
Health Level 7, 387, 390-397, 406, 411- DNA analysis, in Campylobacter
413, 415 identification, 495-496
Hierarchical Message Definition, 395 medicolegal applications of, 828
Logical Observation Identifier Names Document Type Definition, in data
and Codes, 310, 387-390, 398-400, exchange, 408-410, 413
405 Domain completeness, in data exchange,
Reference Information Model, 393-395 398-399, 404
Systemized Nomenclature of Human Down syndrome, acute myeloid leukemia
and Veterinary Medicine, 388-389, in, 188
400, 402-405 hematology of, 158-160, 165
Data model (information model), in data prenatal diagnosis of, 247
exchange, 390-397 transient leukemia in, 157-167
D-dimer test, in pediatric patients, 6 clinical features of, 158-160
Dendritic cells, disorders of, classification diagnosis of, 160-163
of, 135-136 hematology of, 158-160
dendrocytomas, 145-146 hepatic fibrosis and, 165
histiocytomas, 145-146 hydrops fetalis and, 163-164
juvenile xanthogranuloma, 142-145 incidence of, 157
Langerhans’ cell, 138-142 nature of, 166
secondary, 142 Drugs, platelet disorders from, 83
markers for, 138
DTD (Document Type Definition), in data
ontogeny of, 136-138 exchange, 408-410, 413
Dendrocytomas, 145-146
Dyskeratosis congenita, diagnosis of, 120,
Desert Shield strain, of Norwalk virus, 679
124
Desmopressin, in platelet disorders, 84
genetic factors in, 120, 124
Diamond-Blackfan anemia, diagnosis of,
hematology of, 116, 123-124
120, 129
hematopoietic culture in, 117
genetic factors in, 120, 128-129
malignancies in, 119, 124
hematology of, 116, 128
physical anomalies in, 115, 123
hematopoietic culture in, 117, 128
Dystrophin gene, molecular tests for, 821
malignancies in, 119, 128
physical anomalies in, 115, 128
prenatal diagnosis of, 245
Diarrhea, 576-578
Aeromonas. See Aeromonas infections. Echinostoma ilocanum infections, 656
Echis assay, for vitamin K deficiency, 54
amebic, 607-608
Economic issues, in regional laboratory
Bacillus cereus toxin, 590-592, 595
Balantidium coli, 634 networks, 338, 343
Community Health System
Campylobacter, 493
Clostridium perfringens toxin, 589-590, (California), 319, 333
595 information management, 373-383
Escherichia coli. See Escherichia coli infec- Edema, circumoral, in trichinosis, 652
tions. Edwardsiella tarda infections, 576-578
Effectiveness, of laboratory, 423-425
Giardia lamblia, 626-627
Norwalk virus, 680 Efficiency, of laboratory, 425-426
Plesiomonas shigelloides, 572-575 Eggs, Clonorchis sin. sis, 657-658
tapeworm, beef, 647-648
rotavirus, 691-703
Salmonella, 475 fish, 646
Shigella, 482 pork, 649
Trichinella spiralis, 652 Electron microscopy, in Norwalk virus and
Vibrio. See Cholera; Vibrio infections. Norwalk-like virus infections, 684
Yersinia enterocolitica, 527-528 in rotavirus infections, 697
Diepoxybutane, in Fanconi’s anemia in transient leukemia, 161-162
diagnosis, 118 Electrophoresis, for sickle cell syndromes,
Diloxanide furoate, in amebiasis, 615 106-108
Direct antiglobulin test, in autoimmune Elliptocytosis, hereditary, hemolytic
hemolytic anemia, 89 anemia in, 96-98
Disease management, information E-mail. See Internet.
technology for, 379-380 Emergency service, improvement of, 326
892 CUMULATIVE INDEX 1999
Emetic toxins, Staphylococcus aureus, 594 audit systems for, 744-750
Endolimax infections, 602, 609, 611 conferences on, 744-745
Entamoeba coli infections, 610 frequency of, 745-746
Entamoeba dispar infections, clinical in frozen sections, 750-752
features of, 606-607 interpretation, 743
diagnosis of, 609-610, 612-615 legal significance of, 752-753
epidemiology of, 605-606 outside consultation on, 750
pathogenesis of, 604-605 reporting, 743-744
prevention of, 616 types of, 743-745
treatment of, 615-616 Erythroblast(s), in neonates, 19-20
Entamoeba hartmanni infections, 610 Erythroblastic leukemia, acute, in pediatric
Entamoeba histolytica infections, 602-607 patients, 191, 216-218
clinical features of, 606-607 Erythroblastosis fetalis, 89-91
diagnosis of, 608-615 Erythrocytes, antigens of, in pediatric
epidemiology of, 605-606 patients, 12
organisms causing, characteristics of, aplasia of, in Diamond-Blackfan anemia,
602-604 128
versus nonpathogenic amebae, 608 transient, 88
pathogenesis of, 604-605 disorders of, prenatal diagnosis of, 244—
prevention of, 616 245
treatment of, 615-616 enzymes of, in pediatric patients, 12,
Enteric fever. See Salmonella infections. 14-15
Enteroadherent/enterohemorrhagic/ membrane defects of, hemolytic anemia
enteroinvasive /enterotoxigenic in, 92-98
Escherichia coli infections. See elliptocytosis, 96-98
Escherichia coli infections. spherocytosis, 92-95
Enterocolitis, Yersinia enterocolitica. See morphology of, in pediatric patients, 5-6
Yersinia enterocolitica infections. normal values for, in fetus, 4
Entero-Test capsule, for giardiasis, 628
in pediatric patients, 5-6, 11-15
Enterotoxins, Bacillus cereus, 590-593, 595
sickling of, 106-109
Clostridium perfringens, 589-590, 595
transfusion of, intrauterine, for fetal hy-
Escherichia coli, 507 drops, 90-91
Staphylococcus aureus, 593-596
Erythroleukemia, acute (M6), in pediatric
Vibrio cholerae, 538
patients, 191, 216-218
Vibrio parahaemolyticus, 539 Erythromycin, in Campylobacter infections,
Yersinia enterocolitica, 525 497
Enumerated value, in information model, in Listeria monocytogenes infections, 564
390 Erythropoiesis, antigens expressed in, 193
Environmental factors, in acute myeloid
Erythropoietin, normal values for, in
leukemia, 188
pediatric patients, 32
Enzyme immunosorbent assays, for
Escherichia coli infections, 505-521
Bacillus cereus toxin, 593 clinical features of, 505-510
for Escherichia coli, 513-515 diagnosis of of, 513-516
for Giardia lamblia, 628-629 epidemiology of, 510-513
for Norwalk virus and Norwalk-like vi- O157:H7 serotype of, 514-516
ruses, 684 pathogenesis of, 505-510
for rotavirus, 698 prevention of, 516-517
Eosinophil(s), normal values for, in treatment of, 516
pediatric patients, 22 Explicit relationships, in data exchange,
Eosinophilia, in trichinosis, 652 398
Eosinophilic variant, of acute Extensible Markup Language, 294,
myelomonocytic leukemia, 211, 213 389-390, 407, 409, 411, 413-415
Epidemiology, molecular, in infections, Eye, edema around, in trichinosis, 652
822-823
Epidermal growth factor receptor, as brain
tumor marker, 840-841
Erdheim-Chester disease, 144-145 Facilitated deployment, in data exchange,
Errors, diagnostic, 743-756 385
analysis of, in quality assurance, Factor V Leiden, molecular tests for,
727-731 821-822
CUMULATIVE INDEX 1999 893
thromboembolism and, 57 Fluorescent probes, in flow cytometry, in
Familial aplastic anemias. See Aplastic acute lymphoblastic leukemia, 171-172
anemia(s), familial. Fluoroscopy, in giardiasis, 629
Familial hemophagocytic syndromes, Folate, normal values for, in pediatric
147-148 patients, 32
Fanconi’s anemia, 114-123 Food and Drug Administration procedure,
diagnosis of, 118, 120-123 for Listeria monocytogenes culture,
genetic factors in, 114, 118, 120-121 554-555
hematology of, 114, 116, 118 Food-borne diseases, Aeromonas infections,
hematopoietic culture in, 117, 122-123 564-571
malignancies in, 119, 123 amebiasis, 601-619
physical anomalies in, 115 anisakiasis, 640, 654-655
prenatal diagnosis of, 121, 123, 245 Bacillus cereus toxins in, 590-593, 595
Fasciola hepatica, 640 bacterial toxins in, 583-599
Fasciolopsis buski, 640, 655-656 Balantidium coli infections, 632-636
Feces, examination of. See Stool botulism, 583-589
examination. Campylobacter infections, 489-504
Ferritin, normal values for, in pediatric cestodes in, 644-650
patients, 30 clonorchiasis, 657-658
Fetus, alloimmune hemolytic anemia of, Clostridium botulinum toxins in, 583-589
89-92 Clostridium perfringens toxins in, 589-590,
autoimmune hemolytic anemia of, 89-91 595
cells from, in maternal blood, for prena- Diphyllobothrium latum infections, 644—
tal diagnosis, 242 646
normal hematologic values in, 2-4 Edwardsiella tarda infections, 576-578
coagulation proteins, 40-41 Escherichia coli infections, 505-521
erythrocytes, 11, 15-16 flukes, 655-658
fetal hemoglobin, 9, 15-16 giardiasis, 621-632
lymphocyte populations, 22 helminthic, 639-660
morphologic distinctions in, 3, 5-6 hepatitis, 661-673
platelets, 10 Heterophyes heterophyes, 655-656
umbilical cord clamping time and, Listeria monocytogenes infections, 553-564
11-12 nematodes in, 640, 650-655
prenatal diagnostic procedures for. See Norwalk and Norwalk-like virus infec-
Prenatal diagnosis. tions, 675-690
Fibrinogen concentration, in pediatric Paragonimus infections, 640, 642-643, 656
patients, 52 Plesiomonas shigelloides infections, 572-
Fibrinolytic system, of pediatric patients, 575
47-49 Pseudoterranova infections, 640, 654-655
Fine-needle aspiration, cytohistologic rotavirus infections, 691-703
correlations of, 724-725 Salmonella infections, 469-477
Fish tapeworm infections, 640, 644-646 Shigella infections, 477-487
Flagellates and ciliates, 621-638 staphylococcal toxins in, 593-596
Flagellates, Giardia lamblia as. See taeniasis, 646-650
Giardiasis. trematodes in, 640-642, 655-658
Floaters, identification of, trichinosis, 640, 650-654
immunohistochemistry in, 800-801 unusual pathogens in, 553-582
Flow cytometry, in leukemia, acute Vibrio infections, 537-552
lymphoblastic. See Acute Yersinia infections, 523-536
lymphoblastic leukemia, flow cytometry Forecasting, information technology for,
in. 375-376
acute myeloid, 196-197 Foreign tissue, identification of,
transient, 161, 163 immunohistochemistry in, 800-801
in reticulocyte count, 18-19 Forensic applications, of molecular testing,
Fluid therapy, for Escherichia coli infections, 828
516 Formal syntax, in data exchange, 398
for rotavirus infections, 699 France, gynecologic cytology in, quality
for Shigella infections, 483 assurance in, 877-884
for Vibrio infections, 547-548 Fresh osmotic fragility test, in
Flukes, 640-642, 655-658 spherocytosis, 93-95
894 CUMULATIVE INDEX 1999
Frozen sections, errors in, detection of, prenatal diagnosis of, 245
750-751 Gram stain, of Campylobacter, 494
turnaround time of, in quality assur- Granulocyte(s), abnormal, in Down
ance, 723-724 syndrome, 165
Fungi, identification of, normal values for, in pediatric patients,
immunohistochemistry in, 799-800 21-22
Gray platelet syndrome, 73
Grimsby strain, of Norwalk virus, 679
Guillain-Barré syndrome, in Campylobacter
Gastroenteritis, 576-578 infections, 493-494
Aeromonas. See Aeromonas infections. Gums, acute myeloid leukemia infiltration
Campylobacter. See Campylobacter infec- of, 189
tions. Gynecologic cytology, cost-effectiveness
Escherichia coli. See Escherichia coli infec- analysis of, 765-769
tions. quality assurance in, in France, 877-884
Listeria monocytogenes, 561-563
Norwalk virus. See Norwalk virus and
Norwalk-like virus infections.
Plesiomonas shigelloides, 572-575 Hair, hypoplasia of. See Cartilage-hair
Salmonella. See Salmonella infections. hypoplasia.
Shigella. See Shigella infections. Haptoglobin, normal values for, in
Vibrio. See Cholera; Vibrio infections. pediatric patients, 30
Yersinia enterocolitica. See Yersinia entero- Hawaii strain, of Norwalk virus, 679
colitica infections. Head hunters, for alternative careers, 459
Genetic factors, in acute myeloid leukemia, Health care, information integration into,
188-189, 197-201 277-297
in bone marrow failure syndromes, 120. organization of, clinical laboratory, 271-
See also specific syndromes. 275
in cancer, molecular tests for, 817-820 hierarchy, 268
in transient leukemia, 160, 163 market factors in, 268-271
Gentamicin, in Listeria monocytogenes network, 271
infections, 564 patient-centered, information technology
Gestational age, versus hematologic for, 381-383
values, 3-4 performance challenges for, 374-375
Giant cells, Touton, in juvenile Health Insurance Portability and
xanthogranuloma, 142-143 Accountability Act of 1996, 352-356
Giardiasis, 621-632 Health Level 7, in data exchange, 387,
asymptomatic, 630 390-397, 406, 411-413, 415
clinical features of, 626-628 Heat-labile antigen classification, for
diagnosis of, 628-629 Campylobacter, 496
epidemiology, 630-632 Heat-labile enterotoxin, Escherichia coli, 507
organism causing, antigenic variation of, Heat-stable enterotoxin, Escherichia coli, 507
627 Heat-stable toxin, Vibrio cholerae, 539
characterization of, 622 Heel puncture, in infants, 7-8
classification controversy over, 621- Helicobacter pylori, molecular tests for, 822,
622 825
genotypes of, 622 Helminthic infections, 639-660
life cycle of, 622-625 cestodes, 644-650
morphology of, 622-625 Diphyllobothrium latum, 640, 644-646
pathogenesis of, 623 Taenia saginata, 640, 646-648
prevention of, 630-632 Taenia solium, 640, 648-650
treatment of, 629-630 common, 640
Giardin gene, detection of, 630 flukes, 640-642, 655-658
Gingival hyperplasia, in acute myeloid nematodes, 640-641, 650-655
leukemia, 189 Anisakis, 640, 654-655
Glanzmann’s thrombasthenia, 82 Pseudoterranova, 640, 654-655
Glucose phosphate isomerase deficiency, Trichinella spiralis, 640, 650-654
hemolytic anemia in, 100 trematodes, 640-642, 655-658
Glucose—-6-phosphate dehydrogenase Clonorchis sinensis, 640, 656-658
deficiency, hemolytic anemia in, 98-99 Echinostoma ilocanum, 656